Industry News
Ora and SERI Forge Groundbreaking Partnership to Advance Ophthalmology Globally
In a move that promises to reshape the future of eye care, Ora, a leading global ophthalmic contract research organization, and the Singapore Eye Research Institute (SERI), a renowned center of excellence in ophthalmology research, have announced a transformative partnership.
The collaboration brings together Ora's extensive experience in ophthalmic drug and device development with SERI's world-class research capabilities. By pooling their resources and expertise, the two organizations aim to accelerate the development of cutting-edge ophthalmology treatments and technologies.
“SERI's outstanding reputation and their proficiency in conducting preclinical studies led by Associate Professor Veluchamy A. Barathi align perfectly with the mission of Ora,” said Stuart Abelson, chairman and CEO of Ora, Inc. “By combining our strengths, we are poised to accelerate the development of innovative therapies at all stages, furthering SERI’s mission as a global center of excellence. We are stepping into a new era of preclinical excellence, ready to tackle the next frontier of ophthalmic innovation."
The partnership will focus on a wide range of ophthalmic areas, including dry eye, myopia, glaucoma, and retinal diseases. Through joint research projects, clinical trials, and knowledge-sharing initiatives, the two organizations aim to accelerate the development and commercialization of novel therapies and devices.
Professor Jodhbir Mehta, MD, executive director of SERI and deputy chief executive officer (Research), SNEC, said, “We are excited to embark on this pivotal partnership with Ora. This collaboration propels us toward realizing SERI’s vision of becoming an international center of excellence in eye and vision research. Our SERI scientists rank among the top 2% globally in ophthalmology, and our unprecedented impact factor in scientific publications showcase our commitment to advancing eye care. By seamlessly integrating our expertise with Ora’s, we aim to provide unmatched preclinical capabilities, accelerating the development of innovative ophthalmic therapies and reinforcing our position as leaders in translating basic science to clinical applications for sight-threatening disorders.”
The partnership will also establish a collaborative ecosystem, encouraging the participation of other industry players, academic institutions, and regulatory bodies. This approach is designed to foster a multidisciplinary approach to innovation, ensuring that the latest advancements in ophthalmology are brought to market efficiently and effectively.